Gastric acid

Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA

Retrieved on: 
Tuesday, June 27, 2023
Tropical ulcer, Marketing, Kidney disease, Enzyme, Tablet, Statistics, Gastric acid, Enzyme inhibitor, Sihuan Pharmaceutical, HKEX, Esophagitis, Drug, Patient, Risk, National Medical Products Administration, CYP, Kidney, The Company, R, PPI, NMPA, Pharmaceutical industry

It is the first drug approved for marketing by Xuanzhu Biopharm, which marks a new milestone for Xuanzhu Biopharm from R&D to commercialization.

Key Points: 
  • It is the first drug approved for marketing by Xuanzhu Biopharm, which marks a new milestone for Xuanzhu Biopharm from R&D to commercialization.
  • Anaprozole Sodium Enteric-coated Tablet is currently the first and only proton pump inhibitor (PPI) fully independently developed in China.
  • Its Phase I-III clinical studies are all based on the Chinese population, so it is more suitable for Chinese patients.
  • The approval of Xuanzhu Biopharm's Anerazole Sodium Enteric-Coated Tablets will bring more treatment options for patients.

Get-A-Grip Glove Adds Xylazine Resistance to Better Protect First Responders

Retrieved on: 
Wednesday, July 26, 2023
Xylazine, Public, Gastric acid, Multimedia, Heroin, Get a Grip, Defence Research and Development Laboratory, DEA, PH, Risk, ARDL, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fentanyl, Food, Medical device, Drug

PH&S Products Get-A-Grip Nitrile Disposable Glove adds Xylazine resistance to better protect first responders.

Key Points: 
  • PH&S Products Get-A-Grip Nitrile Disposable Glove adds Xylazine resistance to better protect first responders.
  • Akron Rubber and Development Laboratories (ARDL) testing showed the Get-A-Grip two-tone, powder-free nitrile glove with a diamond pattern maintained resistance to xylazine for up to 240 minutes of exposure.
  • This test proves the Get-A-Grip glove will provide protection from xylazine exposure for law enforcement officers, first responders, healthcare workers, and others who might come into accidental contact with the substance.
  • Adding xylazine resistance to a product that already includes resistance to the big three—fentanyl, heroin, and gastric acid—will help keep more professionals safe as they increasingly come in contact with these dangerous substances.

Prodrugs: pills your body converts into an illicit drug can evade detection, but we don't know how big the problem is

Retrieved on: 
Monday, July 24, 2023
Psychoactive drug, Cognition, Seizure, Legislation, GHB, Misuse of Drugs Act 1971, Urine, Plasma protein binding, Enzyme, Ground substance, Human, Gastric acid, Psychoactive Substances Act 2016, Emotion, LSD, COVID, Cell, Carbon, Heroin, Prodrug, GBL, Government, Stomach, Abuse, Protein, Cocaine, Metabolism, Police, Blood, Adderall, Non-Euclidean geometry, Cannabis, Ketamine, Prohibition, Death, MDMA, Saliva, Drug, Medicinal plants, Jet fuel, Medical device, Pharmaceutical industry

Prodrugs are substances that can only cause an effect after being broken down by enzymes in the digestive system or other chemical reactions in the body.

Key Points: 
  • Prodrugs are substances that can only cause an effect after being broken down by enzymes in the digestive system or other chemical reactions in the body.
  • Most illicit drugs work by interacting with specific brain cell receptors, stimulating or blocking the release of chemicals called neurotransmitters.
  • They last for a short time before being transformed into inactive or less active chemicals, which are then eliminated from the body, usually in urine.
  • For prodrugs, however, a small part of the molecule needs to be removed or substituted before it can act on those receptors.

Hard to detect

    • A major problem with prodrugs is they are difficult to detect.
    • Police forces need reference samples to compare the drug with, or advanced equipment to discover its molecular structure.
    • It also explains why many have only appeared in police reports in the past decade.
    • For biological samples (such as blood, urine or saliva), there is another difficulty.

Daewoong Pharmaceutical's Fexuprazan takes its first step into Africa Entering into a partnership with Cooper Pharma, the No. 1 pharmaceutical company in Morocco in the field of digestive health

Retrieved on: 
Monday, July 24, 2023
Agreement, Half-life, Gastric acid, Sale, Gastroesophageal reflux disease, GERD, PPI, Pharmaceutical industry, Daewoong Pharmaceutical

The partnering company is Cooper Pharma, a leading Moroccan pharmaceutical company with presence in Africa and Middle East.

Key Points: 
  • The partnering company is Cooper Pharma, a leading Moroccan pharmaceutical company with presence in Africa and Middle East.
  • Cooper Pharma, founded in 1933, has rapidly expanded its businesses in the pharmaceutical industry, keeping its number one ranking position in Morocco's PPI market, which was estimated to be around KRW75.5 billion in revenue last year.
  • Daewoong intends to propose a new innovative solution to GERD drugs building on Cooper Pharma's significant market dominance and network.
  • By entering into this Agreement, Daewoong Pharmaceutical plans to expand its presence of P-CAB drug Fexuprazan in the African pharmaceutical market for gastroesophageal reflux disease (GERD).

Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

Retrieved on: 
Friday, May 19, 2023
Disulfiram-like drug, Sung, Gastrointestinal disease, IIT, Esophagitis, Sun Yat-sen University, Gastroenterology, EE, Clinical trial, Sun, Gastric acid, Gastroesophageal reflux disease, Konkuk University, DDW, PPI, GERD, Patient, Safety, Pharmaceutical industry, Daewoong Pharmaceutical, Esomeprazole

SEOUL, South Korea and CHICAGO, May 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 19th that they set up a booth at the Digestive Disease Week® 2023 (DDW 2023) held in Chicago, USA and revealed new clinical data through two poster sessions demonstrating the efficacy and safety of Fexuclue® (active ingredient name: Fexuprazan) on patients with gastroesophageal reflux disease (GERD).

Key Points: 
  • The IIT led by Sung In-Kyung, a professor of gastroenterology at Konkuk University, assessed the efficacy and safety of Fexuprazan in patients with erosive esophagitis.
  • The study compared the outcomes of patients who took the investigational product once a day before and after food intake.
  • We anticipate that the investigational use of Fexuprazan will exhibit excellent efficacy in other conditions resulting from excessive gastric acid secretion."
  • We will concentrate our resources on gathering data that can demonstrate the efficacy of Fexuprazan and developing various formulations to enhance the value of Fexuprazan."

Global Drug Conjugates Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Health, Pharmaceutical, Research, Industry, Prevalence, Cancer, Growth, Toxicity, Control, Tissue, Absorption, Metabolism, Smoke, Gastric acid, Cell, R, Awareness, COVID-19, Pharmaceutical industry, Vaccine, Fine chemical, Potash

Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule.

Key Points: 
  • Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule.
  • Key Questions Answered in This Report:
    How has the global antibody drug conjugates market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global antibody drug conjugates market?
  • What is the structure of the global antibody drug conjugates market and who are the key players?

Global Aquafeed Market Size, Share & Trends Analysis Report 2022-2030: Rising Consumption of Aquafeed by Protein Rich Species Carp, Catfish, Salmon and Shrimp - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 14, 2022
Other Natural Resources, Natural Resources, Dry, Infection, Mineral, Animal, Potassium, Gastric acid, Mercury, Salmon, Salmonella, Form, Aquaculture, Mortality, Parasitism, Sea bass, COVID-19, Salt, Escherichia coli, Food industry, USD, Protein, Application, Trout, CAGR, Immune system, Growth, Selenium, Magnesium, Poultry, Industry, Tilapia

The global aquafeed market is expected to reach USD 102.2 million by 2030, registering a CAGR of 4.4% from 2022 to 2030.

Key Points: 
  • The global aquafeed market is expected to reach USD 102.2 million by 2030, registering a CAGR of 4.4% from 2022 to 2030.
  • The growth is majorly driven by the rising consumption of aquafeed by species like carp, catfish, salmon, and shrimps among others due to its rich protein content.
  • The widespread fish mortality due to various infections which are caused by parasites is driving the demand for the consumption of anti-parasites.
  • These feed products are consumed by various warm-water and cold-water fish species such as catfish, salmon, trout, tilapia, shrimps, largemouth bass, and eel among others.

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting

Retrieved on: 
Monday, June 6, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lynx, ALT, Electrolyte, Constipation, Adult, Histology, Indigestion, Enzyme inhibitor, Antidiarrhoeal, Capecitabine, Nausea, HER3, CYP3A4, Fatigue, Abdominal pain, Food, Gastric acid, Puma Biotechnology, Arthralgia, Back pain, Dizziness, Upper respiratory tract infection, MBC, HER2, Appetite, FDA, Puma, Patient, Trastuzumab, Fetus, Kidney, Risk, Tablet, AST, Fulvestrant, Vomiting, Royal commission, Spasm, Diarrhea, Birth, Degenerative disease, Urinary tract infection, Stomatitis, European Commission, Transaminase, Rash, Fourth grade, Abdominal distension, Hepatotoxicity, Nosebleed, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Antacid, Neoplasm, Breast cancer classification, Safety, Pharmaceutical industry, Medical imaging, Vaccine

Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers.

Key Points: 
  • Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers.
  • We are very pleased with the updated activity seen with the combination of neratinib plus trastuzumab plus fulvestrant therapy in this heavily pretreated metastatic breast cancer patient population with HER2-mutated disease.
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
  • Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.

Testing Confirms Fentanyl-Heroin Resistant Glove

Retrieved on: 
Tuesday, May 31, 2022
National Fire Academy, Dizziness, Public health, Morphine, Multimedia, MINERVA, PH, Get a Grip, ARDL, NFPA, FDA, DEA, Drug, Gastric acid, Safety, ASTM, Heroin, Akron, Ohio, Friends, LLC, Medical device, Pharmaceutical industry, Fentanyl

MINERVA, Ohio, May 31, 2022 /PRNewswire/ -- P H & S Products, LLC has been awarded by the FDA a 510(k) medical device Class I listing for a two-tone single-use only, examination grade glove for protection against fentanyl, heroin, and gastric acid per the ASTM D6978-05 standard. Using these 510(k) numbers, the FDA regulates and certifies the safety of these products to provide a barrier for the bare hand encountering these opioids alone or a mixture of all three substances.

Key Points: 
  • Ohio Glove Company Announces FDA 510(k) Medical Approval for Get-A-Grip and Intercept Free Nitrile Glove for First Responder Personal Protection.
  • PH&S Products awarded by the FDA a 510(k) medical device Class 1 listing for protection against fentanyl, heroin.
  • The 510(k) certifications were awarded to both the Get-A-Grip two tone powder free, nitrile glove with a diamond grip pattern and the Intercept Free powder free nitrile NFPA (National Fire Protective Agency) approved two tone, accelerator free glove.
  • ARDL testing showed the fentanyl, heroin and gastric acid did not permeate the gloves up to 240 minutes of exposure.

Antidiarrhoeals Global Market Report 2022 Featuring GSK, Actelion, Perrigo, Lupin and Glenmark Pharmaceuticals, Merck & Co., Pfizer, Proctor & Gamble, Sanofi Aventis and Bayer - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 12, 2022
Health, Pharmaceutical, Pancreas, Merck & Co., Diarrhea, Code, Sale, Stomach, Crohn's disease, Death, Growth, Plasma protein binding, UNICEF, Protecting agent (shipping), Liver, Biotechnology, Disease, Gallbladder, Gastric acid, Kaopectate, Procter & Gamble, Health, Rectum, Loperamide, GlaxoSmithKline, Organic acid, US Foods, International Centre for Diarrhoeal Disease Research, Bangladesh, Glenmark Pharmaceuticals, Esophagus, Animal, CFR, FDA, OTC, Protein, Acquisition, Medical device, Fine chemical, Dietary supplement, Pharmaceutical industry, Bayer, Pfizer, Sanofi

The "Antidiarrhoeals Global Market Report 2022, Drug Class, Application, Type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antidiarrhoeals Global Market Report 2022, Drug Class, Application, Type" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the antidiarrhoeals market are GlaxoSmithKline, Actelion, Perrigo, Lupin and Glenmark Pharmaceuticals, Merck & Co., Pfizer, Proctor & Gamble, Sanofi Aventis and Bayer.
  • Mucosal protective agents are drugs which safeguard the stomach's mucosal lining from gastric acid and are employed to cure peptic ulcers.
  • Rise in the number of diarrhea cases significantly contributes to the growth of antidiarrhoeal drugs market.